GRAIL
GRAL
$64.40
-10.16%
GRAIL, Inc. is a healthcare company focused on pioneering multi-cancer early detection (MCED) through a blood test designed to identify cancers across all stages and types, operating within the Medical Diagnostics & Research industry. The company is a disruptor and potential leader in the nascent but high-stakes liquid biopsy market, aiming to shift cancer diagnosis to earlier, more treatable stages. The current investor narrative is intensely focused on the company's path to commercialization and achieving scale, with recent stock volatility likely tied to pivotal data readouts, regulatory milestones, or reimbursement progress for its flagship Galleri test, as it transitions from a high-burn R&D entity to a commercial-stage enterprise.…
GRAL
GRAIL
$64.40
GRAL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GRAIL's 12-month outlook, with a consensus price target around $83.72 and implied upside of +30.0% versus the current price.
Average Target
$83.72
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$52 - $84
Analyst target range
The stock is covered by 7 analysts, with recent institutional ratings showing a mix of 'Buy' and 'Equal Weight' or 'Outperform' stances, indicating a generally bullish but cautious consensus. The average revenue estimate for the company is $492.5 million, with a range from $455.4 million to $528.6 million, providing a concrete target for the commercial ramp but no explicit price target is given in the data. The wide revenue estimate range signals high uncertainty around the pace of adoption and reimbursement for GRAIL's test, with the high-end target likely assuming successful market penetration and the low-end reflecting more conservative uptake scenarios. The lack of a published average price target and the focus on revenue estimates suggest analysts are primarily modeling the company's path to sales scale rather than near-term profitability, which is typical for a company at this stage of development.
Bulls vs Bears: GRAL Investment Factors
The bull case, supported by improving gross margins, strong liquidity, and powerful recent price momentum, currently has stronger near-term evidence, as reflected in the stock's 44% monthly surge. However, the bear case, anchored by extreme valuation, deep losses, and high volatility, presents a formidable long-term risk. The single most important tension in the investment debate is whether GRAIL can scale revenue fast enough to justify its 21x PS multiple before its cash runway depletes. The resolution hinges on the company's ability to translate its promising technology into accelerating, profitable sales, moving from a story stock to a fundamentals-driven growth company.
Bullish
- Strong Commercialization Momentum: Revenue grew 13.97% YoY to $43.6M in Q4 2025, and quarterly revenue has increased sequentially from $31.8M in Q1 2025, demonstrating initial commercial traction for the Galleri test. Analyst consensus expects revenue to surge to $492.5M, implying a massive growth runway if execution succeeds.
- Rapid Path to Gross Profitability: Gross margin improved dramatically to -25.54% in Q4 2025 from -81.99% in Q1 2024, signaling the company is scaling efficiently and moving toward positive unit economics. This trend is critical for a pre-profit company to eventually achieve operational self-sufficiency.
- Robust Balance Sheet with Low Leverage: The company has a strong current ratio of 11.97 and a minimal debt-to-equity ratio of 0.038, providing ample liquidity to fund its cash burn and growth without near-term solvency risk. This financial flexibility is a key advantage in the capital-intensive diagnostics market.
- Powerful Technical Reversal Underway: The stock price has surged 44.25% over the past month and 74.40% over the past year, breaking a severe downtrend and indicating a potential fundamental re-rating. The current price of $71.68 is 35% above its 52-week low, suggesting the worst may be priced in.
Bearish
- Extreme Valuation on Current Sales: The stock trades at a trailing PS ratio of 21.37x, an extremely high multiple that prices in near-perfect execution of massive future revenue growth. This leaves no margin for error and makes the stock vulnerable to multiple compression if growth disappoints.
- Severe and Persistent Losses: The company reported a Q4 2025 net loss of -$99.2M and a trailing twelve-month free cash flow burn of -$299.0M, indicating it is far from profitability. With a gross margin still deeply negative at -25.54%, the path to positive earnings is long and uncertain.
- High Volatility and Speculative Trading: The stock has a 52-week range of $29.95 to $118.84 and experienced a -62.92% max drawdown, including a crash from over $100 to ~$43 in February 2026. This extreme volatility, coupled with a short ratio of 12.31, reflects high skepticism and a news-driven, speculative profile.
- Revenue Base Remains Very Small: Despite growth, Q4 2025 revenue of $43.6M is minuscule relative to the company's $3.15B market cap, highlighting the immense scaling challenge ahead. The company must grow sales over 10x just to meet the average analyst estimate of $492.5M.
GRAL Technical Analysis
The stock is in a volatile recovery phase within a broader downtrend, having lost 35.07% over the past six months but posting a strong 74.40% gain over the past year. The current price of $71.68 sits approximately 35% above its 52-week low of $29.95 but remains 40% below its 52-week high of $118.84, indicating it is recovering from a deep trough but still far from its previous peak, suggesting significant technical damage was incurred earlier in the year. Recent momentum is decisively positive, with the stock surging 44.25% over the past month and 34.66% over the past three months, sharply diverging from the negative six-month trend and signaling a powerful short-term reversal, potentially driven by a fundamental catalyst. Key technical support is at the 52-week low of $29.95, while immediate resistance is the recent high of $73.92 from late May; a sustained breakout above this level could signal the continuation of the recovery trend, while a failure would suggest consolidation. The stock's high volatility is evident from its price action, which saw a dramatic intra-month drop from over $100 to near $43 in February, underscoring its speculative and news-driven nature.
Beta
—
—
Max Drawdown
-62.9%
Largest decline past year
52-Week Range
$30-$119
Price range past year
Annual Return
+67.7%
Cumulative gain past year
| Period | GRAL Return | S&P 500 |
|---|---|---|
| 1m | +19.1% | +5.3% |
| 3m | +22.1% | +11.5% |
| 6m | -36.4% | +10.9% |
| 1y | +67.7% | +28.7% |
| ytd | -27.5% | +11.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GRAL Fundamental Analysis
Revenue is growing but from a very low base, with the most recent Q4 2025 revenue of $43.6 million representing a 13.97% year-over-year increase, yet the sequential trend from Q1 2025 ($31.8M) to Q4 2025 shows quarterly growth is stabilizing but not yet accelerating meaningfully. The company is deeply unprofitable, with a Q4 2025 net loss of -$99.2 million and a gross margin of -25.54%, indicating its cost of revenue still exceeds its sales, a sign of an early-stage commercial model with significant scaling challenges; however, the gross margin has improved from -81.99% in Q1 2024, showing progress on the path to gross profitability. The balance sheet shows a strong current ratio of 11.97 and a minimal debt-to-equity ratio of 0.038, indicating ample liquidity and low leverage, but the company is burning substantial cash, with a trailing twelve-month free cash flow of -$299.0 million and an operating cash flow of -$63.8 million in the last quarter, meaning it is heavily reliant on external financing to fund its ongoing losses and growth investments.
Quarterly Revenue
$43597000.0B
2025-12
Revenue YoY Growth
+0.13%
YoY Comparison
Gross Margin
-0.25%
Latest Quarter
Free Cash Flow
$-299007000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GRAL Overvalued?
Given the company's negative net income and EBITDA, the Price-to-Sales (PS) ratio is the most appropriate primary valuation metric. The trailing PS ratio is an extremely high 21.37x, reflecting the market's premium valuation for its disruptive growth potential despite minimal current sales. There is no direct industry average PS ratio provided for comparison, but such a high multiple is typical for pre-profit, high-potential biotech disruptors and suggests the market is pricing in massive future revenue growth rather than current fundamentals. Historically, the stock's PS ratio has compressed dramatically from 79.95x at the end of 2025 to the current 21.37x, primarily due to the significant increase in share price being outpaced by even greater revenue growth; this indicates the valuation is becoming less extreme on a sales basis as the business scales, though it remains elevated relative to its own history.
PE
-7.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -19x~0x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-7.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: GRAIL faces severe financial risks stemming from its deeply unprofitable operations. The company is burning cash at an alarming rate, with TTM free cash flow of -$299M and an operating cash flow of -$63.8M in the last quarter alone. Despite a strong balance sheet (current ratio of 11.97), this burn rate necessitates future capital raises, risking shareholder dilution. Furthermore, revenue concentration is absolute, with 100% dependence on the Galleri test, and gross margins, while improving, remain negative at -25.54%, indicating the core business model is not yet economically viable on a per-unit basis.
Market & Competitive Risks: The primary market risk is valuation compression. Trading at a PS ratio of 21.37x, the stock is priced for flawless execution of a massive total addressable market. Any disappointment in revenue growth, reimbursement approvals, or competitive launches could trigger a severe de-rating, as seen in the stock's 62.9% max drawdown. The stock exhibits high volatility and negative 6-month relative strength (-45.8% vs. SPY), indicating it is highly sensitive to sentiment shifts and sector rotation away from speculative growth. Emerging competitive threats in the liquid biopsy space could also pressure pricing and market share.
Worst-Case Scenario: The worst-case scenario involves a combination of slower-than-expected Galleri adoption, reimbursement setbacks from payers, and a broader market downturn compressing growth stock multiples. This could lead to missed revenue targets, forcing the company to raise capital at a depressed valuation, severely diluting shareholders. In this adverse scenario, the stock could realistically revisit its 52-week low of $29.95, representing a downside of approximately -58% from the current price of $71.68. The high short interest (ratio of 12.31) suggests a cohort of investors is positioned for such an outcome.